Clinical characteristics in different groups
| Characteristics | Group 1 (N = 1,601) | Group 2 (N = 92) | Group 3 (N = 826) | Group 4 (N = 137) | P value |
|---|---|---|---|---|---|
| CAVI | 8.49 ± 1.33 | 8.20 ± 1.15* | 8.56 ± 1.33# | 8.43 ± 1.18 | 0.085 |
| Calcium channel blocker (%) | 21.55 | 15.22 | 26.39 | 9.49 | < 0.001 |
| Angiotensin-converting enzyme inhibitors (%) | 3.94 | 4.35 | 3.87 | 4.38 | 0.988 |
| Angiotensin II receptor blocker (%) | 13.30 | 13.04 | 17.92 | 10.95 | 0.011 |
| Beta blockers (%) | 9.93 | 4.35 | 12.47 | 5.84 | 0.013 |
| Glycosidase inhibitors (%) | 8.68 | 8.70 | 9.32 | 8.76 | 0.964 |
| Metformin (%) | 8.12 | 5.43 | 9.08 | 5.84 | 0.430 |
| Sulfonylureas (%) | 3.56 | 2.17 | 4.72 | 2.19 | 0.287 |
| Insulin (%) | 2.56 | 7.61 | 3.87 | 2.92 | 0.052 |
| Statins (%) | 23.30 | 21.74 | 27.97 | 15.33 | 0.004 |
Comparisons between multiple groups were used by analysis of variance. Proportions were analyzed by χ2-test. * vs Group 1, P < 0.05; # vs Group 2, P < 0.05. Group 1: subjects with normal TG and LDL-C; Group 2: subjects with normal TG and hyper-LDL-C; Group 3: subjects with hypertriglyceridemia and normal LDL-C; Group 4: subjects with hypertriglyceridemia and hyper-LDL-C. CAVI: cardio-ankle vascular index